Dr Lal PathLabs Q1 profit up, INR 5 dividend, two acquisitions approved

Listed Co AcquisitionStrategic Transactions View source PDF Explain this filing

LALPATHLAB · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+4.7%Reaction day

₹1690.10

prior close

₹1696.50

announcement price

In-mkt

timing

Nifty Smallcap 250market-0.3%+5.0% vs market

Healthcare Service Provider peers, median of 23sector-0.1%+4.8% vs sector

On the reaction day the stock moved 5.0 pts more than Nifty Smallcap 250 and 4.8 pts more than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.2

10m

+0.1

15m

+0.3

30m

+2.1

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+4.7-0.3+5.0-0.1+4.8

Next day

+7.7+1.0+6.7+0.3+7.4

+6.8+0.5+6.3+0.2+6.6

+11.2+1.9+9.3+0.7+10.5

+10.6+1.1+9.5-0.8+11.4

+12.4+1.5+10.9-0.2+12.6

+11.7+3.1+8.6+1.8+9.8

15d

+13.0+3.6+9.5-1.8+14.8

+12.3+4.1+8.2-0.9+13.2

+15.8+2.9+12.9-0.3+16.1

+9.8-6.1+15.9-11.1+20.9

UpDownMarket · Nifty Smallcap 250Sector · Healthcare Service Provider peers, median of 23Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Dr Lal PathLabs Q1 FY27 consolidated revenue rose to INR 7,977 Mn (vs 6,698 Mn YoY), PAT at INR 1,705 Mn vs 1,340 Mn. Board declared interim dividend of INR 5 per share, record date July 30. Also approved 119,300 stock options under RSU Plan 2025. Two acquisitions cleared: 80 percent stake in Ghana-based Sunshine Healthcare for GHS 45.6 Mn (around INR 380 Mn), and 30 percent stake in Neuome Technologies for up to INR 35 Mn.

Likely market impact

Strong Q1 earnings and dividend payout lift shareholder returns; Africa and biobanking deals signal growth push beyond core India diagnostics.